Kidney Diseases  >>  Tekturna (aliskiren)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tekturna (aliskiren) / PDL
NCT00097955: Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria

Completed
2
496
US, Canada, Europe, RoW
aliskiren
Novartis Pharmaceuticals
Diabetic Nephropathy
04/07
04/07
ARIA, NCT01302899 / 2009-012196-10: To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy

Terminated
2
8
Europe
Aliskiren, Placebo to Aliskiren, Hydrochlorothiazide (HCTZ), Placebo to Hydrochlorothiazide (HCTZ), Ramipril
Novartis Pharmaceuticals
Non-diabetic Nephropathy
12/11
12/11
ARIANA-CHF-RD, NCT00881439: Safety and Efficacy Study of Add On Aliskiren in Patients With Heart Failure and Renal Impairment

Terminated
2
41
Europe
Aliskiren, Rasilez, SPP100, Placebo
University Medical Center Groningen
Heart Failure, Kidney Failure
07/12
12/12
NCT00461136 / 2005-000361-19: Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes

Completed
1/2
18
Europe
Aliskiren
Novartis
Diabetes Type 2
11/06
11/06
NCT00464880 / 2005-000362-39: Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy

Completed
1/2
24
Europe
Aliskiren
Novartis
Diabetes Type 2
 
11/07
NCT00464776 / 2005-000286-19: Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy

Completed
1/2
26
Europe
Aliskiren, SPP100
Novartis
Diabetes Mellitus, Type 2
04/08
 

Download Options